Part

Omega Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 1, 2023
Acute respiratory distress syndrome, Safety, Therapy, Reuters, Culture, Investigational New Drug, Research, Lung cancer, Clinical trial, IND, G&A, Pharmacokinetics, Security, Part, FDA, Standard of care, Hepatocellular carcinoma, Patient, Multiple, R, Omega, NSCLC, OEC, OMEGA, Messenger, MYC, Gastrointestinal cancer, HCC, Society, COVID, Cryptocurrency, Pharmaceutical industry, Medical imaging

“2022 was a pivotal year for Omega, marked by tremendous progress and consistent execution.

Key Points: 
  • “2022 was a pivotal year for Omega, marked by tremendous progress and consistent execution.
  • Research and development (R&D) expenses for the fourth quarter of 2022 were $25.7 million, compared to $14.7 million for the fourth quarter 2021.
  • General and administrative (G&A) expenses for the fourth quarter of 2022 were $5.4 million, compared with $5.7 million for the fourth quarter of 2021.
  • Net loss for the fourth quarter of 2022 was $30.8 million, compared with $20.9 million for the fourth quarter of 2021.

Kohl's Reports Fourth Quarter and Full Year Fiscal 2022 Financial Results

Retrieved on: 
Wednesday, March 1, 2023
Men, Other Retail, Online Retail, Family, Discount, Variety, Department Stores, Specialty, Consumer, Fashion, Retail, Other Consumer, Women, Footwear, SG, NYSE, Operating cost, Partnership, Part, Sephora, General Administration of Press and Publication, KSS, Capital expenditure, Video game, Reinsurance, Music

Kohl’s Corporation (NYSE:KSS) today reported results for the quarter and year ended January 28, 2023.

Key Points: 
  • Kohl’s Corporation (NYSE:KSS) today reported results for the quarter and year ended January 28, 2023.
  • Tom Kingsbury, Kohl’s chief executive officer, stated, “Kohl’s fourth quarter results reflect meaningful proactive measures we took to better position the business for 2023, as well as sales pressure driven by the ongoing persistent inflationary environment.
  • Clearance markdowns impacted margin by approximately 750 basis points and product cost inflation impacted margin by approximately 200 bps.
  • Operating cash flow was $707 million driven by improvements in working capital during the fourth quarter of 2022.

EMEA Enterprises Increase Cloud Storage Spending as Cloud Adoption Heightens and Hidden Fees Bite

Retrieved on: 
Wednesday, March 1, 2023
Software, Networks, Internet, Hardware, Data Management, Technology, Mobile, Wireless, Security, Cloud, Smith, Organization, Research, Part, ISO, GDPR, IDC, Paramount, Wasabi Technologies, API, Video game, Arms industry, Medical device, Online shopping

However, many EMEA organisations struggle to manage the fee and cost structures associated with public cloud storage.

Key Points: 
  • However, many EMEA organisations struggle to manage the fee and cost structures associated with public cloud storage.
  • EMEA prioritising cloud storage over on-premises storage, but security concerns remain paramount
    87% of enterprises migrated storage from on-premises to public cloud in 2022, with Germany and the Netherlands exceeding the EMEA average at 98%, and 97% respectively.
  • EMEA enterprises plan to increase spending on cloud storage, but struggle with managing cost and fees
    EMEA enterprises allocate an average of 14% of their total IT budget to cloud storage, compared to the global average of 12%, and 81% plan to increase their cloud storage budget in 2023.
  • Overall, EMEA respondents indicate that 48% of their cloud storage bill is allocated to fees, and 51% allocated to storage capacity, on average.

Asia-Pacific Leads Global Public Cloud Storage Growth in 2023; 85% of Businesses Increasing Amount of Data Stored in Public Cloud According to Wasabi Global Cloud Storage Index

Retrieved on: 
Tuesday, February 28, 2023
Networks, Internet, Data Management, Mobile, Wireless, Technology, Cloud, Wasabi Technologies, API, Organization, Overalls, IDC, Prevalence, Research, Part, Video game, Medical imaging, Wasabi

Asia-Pacific organizations are embracing the public cloud to store fast-growing volumes of data, specifically for backup, archive and disaster recovery initiatives, but are hit the hardest by public cloud storage fees compared to their global counterparts, according to Part 2 of Wasabi’s 2023 Global Cloud Storage Index.

Key Points: 
  • Asia-Pacific organizations are embracing the public cloud to store fast-growing volumes of data, specifically for backup, archive and disaster recovery initiatives, but are hit the hardest by public cloud storage fees compared to their global counterparts, according to Part 2 of Wasabi’s 2023 Global Cloud Storage Index.
  • Part 2 of the Wasabi 2023 Global Cloud Storage Index presents results from 200 IT decision-makers across Australia, Japan and Singapore.
  • Wasabi commissioned independent market research agency Vanson Bourne to conduct research into cloud storage.
  • The study surveyed 1,000 IT decision makers who had at least some involvement in or responsibility for public cloud storage purchases in their organization.

Leading Audiobook Producer Greenlights Publishing Company For Independent Authors

Retrieved on: 
Tuesday, February 28, 2023
Marketing, Audie Awards, Audio Publishers Association, Go Home, Publishing, Pulitzer Prize, Audible (service), Apple Books, Part, Hulu, The New York Times, Mechanics, Marvel vs. Capcom 2: New Age of Heroes, Pioneer, Press, Lantern Books, Audiobook, Generation, Lantern

ATLANTA, Feb. 28, 2023 /PRNewswire/ -- Lantern Books launches as the world's first full-scale audiobook production and publishing company dedicated to independent authors. For decades, Lantern Audio has been a trusted audiobook production partner for the largest publishers in the world. Recognizing the importance of catering services to independent authors, Lantern now offers full-scale publishing and studio services. The award-winning team at Lantern Books is dedicated to helping indie authors navigate through important decisions and the process of creating, distributing and marketing an audiobook.

Key Points: 
  • ATLANTA, Feb. 28, 2023 /PRNewswire/ -- Lantern Books launches as the world's first full-scale audiobook production and publishing company dedicated to independent authors.
  • Recognizing the importance of catering services to independent authors, Lantern now offers full-scale publishing and studio services.
  • Founder Chris Fogg states, "Many Independent Publishers and Self-Published authors don't have the connections or time to handle the mechanics and financial side of audiobook distribution and marketing.
  • Our world-class publishing and marketing team offers tools to reach the largest and most lucrative audience possible for your audiobook."

Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

Retrieved on: 
Tuesday, February 28, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Headache, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Safety, Paroxysmal nocturnal hemoglobinuria, PNH, IgA nephropathy, MBA, Immunoglobulin A, Part, Patient, Toxicity, Trial of the century, Arrowhead, Arrowhead Pharmaceuticals, C5, Allergen, Part Two, COVID-19, Pharmacokinetics, RNA, RNA interference, Pharmaceutical industry, Vaccine, C3

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production of complement component 3 (C3) as a potential therapy for various complement mediated diseases.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production of complement component 3 (C3) as a potential therapy for various complement mediated diseases.
  • The company plans to present additional results at an upcoming complement-focused medical meeting.
  • Dosing in Part 2 of the Phase 1/2 study is expected to begin in the first half of 2023.
  • “Substantial unmet medical need remains in the treatment of multiple complement mediated diseases, including IgA nephropathy, C3 glomerulopathy, paroxysmal nocturnal hemoglobinuria, and additional renal and hematologic indications, despite the availability of approved complement C5 inhibitors that have significantly improved treatment.

Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program

Retrieved on: 
Tuesday, February 28, 2023
Biotechnology, Alternative Medicine, Health, Mental Health, DMT, Generalized anxiety disorder, PD, Depression, Deuterium, NYSE, Research, Absorption, Massachusetts General Hospital, Patient, NEO, MGH, Plasma, Harvard Medical School, Acceleration, Inc., Psychedelic drug, Calendar, Psychiatry, IV, Dean (education), PK, Hospital, Pharmaceutical industry, Part

Interim findings from the Company's ongoing Phase 1/2a clinical trial evaluating CYB003 demonstrated positive observations, including a rapid and short-acting psychedelic response in participants.

Key Points: 
  • Interim findings from the Company's ongoing Phase 1/2a clinical trial evaluating CYB003 demonstrated positive observations, including a rapid and short-acting psychedelic response in participants.
  • As of the date of this press release, Phase 1 dosing has been completed and the Phase 2a portion of the trial has commenced.
  • Cybin expects to report top-line results from the completed Phase 1/2a clinical trial in late third quarter of calendar year 2023.
  • The Company will provide further information on the interim readout from its ongoing CYB003 Phase 1/2a trial and additional updates on its CYB004 program.

Hims & Hers Health, Inc. Reports Record Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Monday, February 27, 2023
General Health, Vitamins, Supplements, Other Health, Health, Pharmaceutical, Net, Financial condition report, EBITDA, Growth, GAAP, Result, Table, Annual report, Adjustment, Hers, Part, Hims & Hers Health, Cryptocurrency, Video game, Bookkeeping, Beauty salon

Revenue was $167.2 million for the fourth quarter of 2022 compared to $84.7 million for the fourth quarter of 2021, an increase of 97% year-over-year.

Key Points: 
  • Revenue was $167.2 million for the fourth quarter of 2022 compared to $84.7 million for the fourth quarter of 2021, an increase of 97% year-over-year.
  • Gross margin was 79% for the fourth quarter of 2022 compared to 73% for the fourth quarter of 2021.
  • Net loss was $(10.9) million in the fourth quarter of 2022 compared to $(31.2) million for the fourth quarter of 2021.
  • Adjusted EBITDA was $3.9 million for the fourth quarter of 2022 compared to $(7.1) million for the fourth quarter of 2021.

Dealer eProcess Selected as a 2023 Google Premier Partner

Retrieved on: 
Monday, February 27, 2023
Spend, Marketing, World Premiere (Partners-N-Crime album), Acura, DMS, Volkswagen, Certification, Ram, Buick, Partnership, Jeep, Chrysler, Land Rover, GMC, Automation, Growth, BMW, OEM, Alfa Romeo, Kia, Dodge, Mitsubishi Group, Part, Google Ads, Fiat, Satellite navigation device, Financial adviser, Cadillac, Dealer, Subaru

LISLE, Ill., Feb. 27, 2023 /PRNewswire-PRWeb/ -- Dealer eProcess is proud to have earned an elite honor in automotive digital marketing by being recognized as a 2023 Google Premier Partner. This status is given to the top 3% of Google partners in the United States and reflects the dedication and marketing proficiency that the DEP Digital Marketing team provides to dealers on their Google Advertising campaigns.

Key Points: 
  • Dealer eProcess is proud to have earned an elite honor in automotive digital marketing by being recognized as a 2023 Google Premier Partner.
  • LISLE, Ill., Feb. 27, 2023 /PRNewswire-PRWeb/ -- Dealer eProcess is proud to have earned an elite honor in automotive digital marketing by being recognized as a 2023 Google Premier Partner.
  • Dealer eProcess has been a part of the Google Partners Program for several years, which is the first qualification to become considered as a Premier Partner.
  • The Google Partners Team adds, "Achieving Premier Partner status is an accomplishment worth celebrating and distinguishes [Dealer eProcess] as a Google Ads expert to clients and the industry.

ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials

Retrieved on: 
Thursday, February 23, 2023
Policy by press release, Asset purchase agreement, Retina, Investment, Partner, Part, Purchasing, Ophthalmology, CNS, Acceleration, LP, Linde plc, ADHD, Sale, Rule, Finance Secretary (India), Regulation D, Disclosure, Note, Pharmaceutical industry, Security (finance)

"We are pleased to have The Lind Partners as an investor," said Howard Doong, CEO of ABVC BioPharma.

Key Points: 
  • "We are pleased to have The Lind Partners as an investor," said Howard Doong, CEO of ABVC BioPharma.
  • "We are pleased to invest in ABVC to support their vision and growth initiatives," said Phillip Valliere, Managing Director at The Lind Partners.
  • "We believe 2023 will be an exciting year for ABVC as their drug pipeline meets expected key milestones."
  • If the Company makes a Monthly Payment in cash, the Company must also pay Lind a cash premium of 5% of such Monthly Payment.